 |
|
|
| |
Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With
Chronic Hepatitis B (Study 103)
|
| |
| |
Reported by Jules Levin
59th Annual Meeting of the American Association for the Study of Liver Disease October 31-November 4, 2008 San Francisco, CA
Oral Presentation # 158
E Jenny Heathcote1, Ed Gane2, Robert deMan3, Sing Chan4, William Sievert5, Stefan Mauss6, Patrick Marcellin7, Jeff Sorbel8, Jane Anderson8, Elsa Mondou8, Joe Quinn8, and Franck Rousseau8
Conclusions Study 103
Week 96
88% of patients (On-treatment) on therapy had HBV DNA <400 copies/mL (78% ITT)
6% achieved HBsAg loss
No resistance detected up to 2 years on TDF monotherapy
Patients can safely and effectively switch from ADV to TDF treatment
TDF was well tolerated through Week 96
TDF demonstrated durable, potent antiviral activity through Week 96
|
| |
|
|
|
|
|
